Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.40 |
| ▸ | THRA | P10827 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1569669 | 0.92 | HTR2C (0.43) | SLC6A4HTR6PTGER1PARP15PARP10 | |
| SCHEMBL15474826 | 0.83 | MAOA (0.48) | MAOAMAOBPARP15PARP10 | |
| SCHEMBL15474787 | 0.81 | PARP10 (0.40) | SLC6A4HTR6THRATHRBMAOA | |
| SCHEMBL13723295 | 0.81 | PARP10 (0.41) | SLC6A4HTR6THRATHRBMAOA | |
| SCHEMBL2376749 | 0.79 | SLC6A2 (0.42) | SLC6A4MAOAMAOBPARP15PARP10 | |
| SCHEMBL16319982 | 0.78 | SCN8A (0.40) | SLC6A4HTR6PTGER1MAOAMAOB | |
| SCHEMBL15474975 | 0.76 | SLC6A4 (0.44) | SLC6A4HTR6PTGER1THRATHRB | |
| SCHEMBL13722740 | 0.76 | PARP10 (0.40) | PARP15PARP10HTR2CHTR2B | |
| SCHEMBL1986158 | 0.76 | MCHR1 (0.41) | MAOAMAOBPARP15PARP10HTR2C | |
| SCHEMBL5672945 | 0.75 | MAOA (0.47) | SLC6A4HTR6MAOAMAOBPARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544684-B1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1) | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-24 | — | — | EP | disclosed |
| US-20110224209-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1) | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224209-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1) | DPP4, DPP3, DPP7 | SLC6A4 310/4885HTR6 843/4885PTGER1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.